Biogen (NASDAQ: BIIB)
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.
The latest price target for Biogen (NASDAQ: BIIB) was reported by Morgan Stanley on Wednesday, May 4, 2022. The analyst firm set a price target for 285.00 expecting BIIB to rise to within 12 months (a possible 40.46% upside). 50 analyst firms have reported ratings in the last year.
The stock price for Biogen (NASDAQ: BIIB) is $202.9 last updated May 17, 2022, 8:00 PM UTC.
There are no upcoming dividends for Biogen.
Biogen’s Q2 earnings are confirmed for Thursday, July 21, 2022.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.